Search research articles
Contact Us
Filters
Showing results (121-130 of 160) with videos related to
Page
of 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Daniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.
Cancer
|
October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations
Mahran Shoukier, Tapan Kadia, Marina Konopleva, et al.
Leukemia & Lymphoma
|
October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy
Jorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.
American Journal of Hematology
|
June 19, 2023
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation
Alexandre Bazinet, Hagop Kantarjian, Naszrin Arani, et al.
Blood Advances
|
November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
Ghayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.
Haematologica
|
July 2, 2026
Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia
Thura Win Htut, Jeannot Kekedjian, Nicholas Short, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 3, 2020
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study
Prithviraj Bose, David McCue, Sebastian Wurster, et al.
Journal of Hematology & Oncology
|
January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
Nicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.
Cancer
|
August 3, 2021
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis
Abhishek Maiti, Courtney D DiNardo, Wei Qiao, et al.
Blood Advances
|
April 22, 2021
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
Curtis A Lachowiez, Sanam Loghavi, Ken Furudate, et al.
Page
of 16
Search research articles
Search
Showing results (121-130 of 160) with videos related to
Sort By:
Page
of 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Daniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.
Cancer
|
October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations
Mahran Shoukier, Tapan Kadia, Marina Konopleva, et al.
Leukemia & Lymphoma
|
October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy
Jorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.
American Journal of Hematology
|
June 19, 2023
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation
Alexandre Bazinet, Hagop Kantarjian, Naszrin Arani, et al.
Blood Advances
|
November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
Ghayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.
Haematologica
|
July 2, 2026
Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia
Thura Win Htut, Jeannot Kekedjian, Nicholas Short, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 3, 2020
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study
Prithviraj Bose, David McCue, Sebastian Wurster, et al.
Journal of Hematology & Oncology
|
January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
Nicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.
Cancer
|
August 3, 2021
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis
Abhishek Maiti, Courtney D DiNardo, Wei Qiao, et al.
Blood Advances
|
April 22, 2021
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
Curtis A Lachowiez, Sanam Loghavi, Ken Furudate, et al.
Page
of 16